Bioventus Inc.BVSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank62
3Y CAGR-60.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-60.8%/yr
vs +51.2%/yr prior
Acceleration
-111.9pp
Decelerating
Percentile
P62
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 2.87% |
| Q3 2025 | -7.85% |
| Q2 2025 | 5.35% |
| Q1 2025 | -7.24% |
| Q4 2024 | -14.76% |
| Q3 2024 | -9.55% |
| Q2 2024 | 60.26% |
| Q1 2024 | -19.47% |
| Q4 2023 | 8.19% |
| Q3 2023 | -11.27% |
| Q3 2023 | -9.89% |
| Q2 2023 | -44.60% |
| Q4 2022 | 47.53% |
| Q4 2022 | -27.52% |
| Q3 2022 | -8.11% |
| Q2 2022 | -2.46% |
| Q4 2021 | 15.44% |
| Q4 2021 | 27.23% |
| Q3 2021 | 410.67% |
| Q2 2021 | -67.24% |
| Q4 2020 | -19.00% |
| Q3 2020 | 37.48% |
| Q2 2020 | 20.97% |
| Q1 2020 | -31.74% |
| Q4 2019 | 10.51% |
| Q3 2019 | 12.41% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q1 2016 | 0.00% |
| Q1 2015 | 0.00% |